|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||78.02 - 80.08|
|52 Week Range||75.62 - 107.25|
|Beta (3Y Monthly)||0.97|
|PE Ratio (TTM)||22.63|
|Earnings Date||Jul 25, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||4.28 (5.39%)|
|1y Target Est||89.73|
These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
An independent data monitoring committee recommended the study be stopped due to "lack of survival benefit" for patients receiving the treatment Depatux-M when compared with a placebo, AbbVie said. Depatux-M, when added to the standard regimen of radiation and temozolomide, failed to meet the main goal of achieving overall survival in newly diagnosed patients when compared to patients given a placebo along with radiation and temozolomide. The trial has been testing the drug to treat an aggressive form of brain cancer known as glioblastoma.
Shares of AbbVie Inc. fell 1.8% in premarket trade after the company announced that interim data from a Phase 3 trial of glioblastoma drug Depatux-M did not show any survival benefit to patients. An independent monitoring committee recommended stopping the trial, which was conducted in collaboration with the RTOG Foundation, a not-for-profit cancer research organization. "Glioblastoma patients and their caregivers face a devastating disease for which there are few therapeutic options. While we are disappointed that Depatux-M did not demonstrate a survival benefit in the INTELLANCE-1 study, we remain committed to discovering and developing therapies to address some of the most debilitating cancers," said Michael Severino, vice chairman and president of AbbVie, in a statement. AbbVie has halted enrollment in all of its Depatux-M studies. Shares of the company have fallen 14% in the year to date through Thursday, while the S&P 500 has gained 14.7%.
NORTH CHICAGO, Ill., May 17, 2019 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma (GBM), whose tumors have EGFR (epidermal growth factor receptor) amplification, demonstrated no survival benefit for patients receiving Depatux-M at an interim analysis. An Independent Data Monitoring Committee (IDMC) recommended the study be stopped due to lack of survival benefit for patients receiving Depatux-M compared with placebo when added to the standard regimen of radiation and temozolomide.
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
- FDA reviewed the submission under the Real-Time Oncology Review pilot program - Approval based on data from the Phase 3 CLL14 trial of VENCLEXTA® (venetoclax) in combination with obinutuzumab® - a randomized ...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Walt Disney Co moved to take full control over Hulu through ...
MC10, Inc., a healthcare technology company specializing in wearable digital health sensors, and AbbVie (ABBV), a research-based global biopharmaceutical company, announced today that the companies are working together on clinical trials designed to explore a range of outcome measures in patients with multiple sclerosis (MS) using the BioStamp nPoint® system. This innovative, patient-focused endeavor aims to explore the use of data from the nPoint® System in order to provide unique insights into MS clinical studies. “We are excited to work with a world leader in CNS therapies and look forward to exploring novel data and metrics that help to advance clinical development” commented Dr Arthur Combs, Chief Medical Officer of MC10.
As uncertainty over the outcome of Sino-American trade talks grows, so does the possibility of a longer-than-expected negotiations or an all-out trade war, strategists at Goldman Sachs are providing some timely trading strategies.
Shares of AbbVie Inc. rose 1.3% in premarket trade Tuseday after the company announced it had resolved its litigation with biosimilar drugmaker Boehringer Ingelheim over U.S. patents for the rheumatoid arthritis drug Humira. Under the terms of the resolution, AbbVie will grant Boehringer a non-exclusive license to its Humira-related intellectual property in the U.S., which will begin in 2023. Boehringer, which is looking to sell a biosimilar version of Humira in the U.S. called Cyltezo, will pay royalties to AbbVie for licensing the patents. AbbVie will not make any payments to Boehringer. Shares of AbbVie have declined 5% so far this year, while the S&P 500 has gained 12%.
NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (ABBV) announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant BI a non-exclusive license to its HUMIRA-related intellectual property in the United States.
NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21, 2019. Michael Severino, vice chairman and president, will present at 7:30 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com.
AbbVie (ABBV) -- spun off from Abbott Labs (ABT) in 2013 -- is a biotechnology company that is focused on the development and commercializing of treatments in immunology, virology, and oncology, notes Ben Reynolds, editor of Sure Dividend.
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
The Parnassus Endeavor Fund (Trades, Portfolio) bought shares of the following stocks during the first quarter. Warning! GuruFocus has detected 4 Warning Signs with ABBV. The fund established a stake in AbbVie Inc. (ABBV), buying 1.7 million shares.
AbbVie Inc NYSE:ABBVView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for ABBV with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABBV. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABBV totaled $604 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.